Scarica l'app Stockscreener
5.89
1.20%
0.07
Dopo l'orario di chiusura:
5.89
Karyopharm Therapeutics Inc Borsa (KPTI) Ultime notizie
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
RA Capital (NASDAQ: KPTI) and partners report 9.99% stake in Karyopharm - Stock Titan
Commodore Group discloses 1.95M KPTI stake; 19,618,032 shares O/S - Stock Titan
KPTI stock slumps pre-market even as Karyopharm’s myelofibrosis treatment meets primary endpoint — retail doubtful about FDA approval - MSN
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Short Interest Up 20.9% in March - MarketBeat
Will Karyopharm Therapeutics Inc benefit from green energy policiesInsider Buying & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Piper Sandler Lowers Price Target for Karyopharm Therapeutics (K - GuruFocus
Piper Sandler Reaffirms "Overweight" Rating for Karyopharm Therapeutics (NASDAQ:KPTI) - MarketBeat
Karyopharm stock price target cut to $8 by Piper Sandler on trial results - ca.investing.com
Karyopharm to seek label expansion for Xpovio in myelofibrosis after late-stage trial win - MSN
Karyopharm Therapeutics Inc (KPTI) Stock Price, Quote, News & History - benzinga.com
Karyopharm Strengthens Liquidity With New Equity Financing - TipRanks
Karyopharm Therapeutics raises $30 million in private placement with RA Capital By Investing.com - Investing.com South Africa
Karyopharm Therapeutics (KPTI) Stock Jumps 6.9%: Will It Continue to Soar? - Yahoo Finance
Karyopharm Therapeutics raises $30 million in private placement with RA Capital - investing.com
HC Wainwright Has Optimistic Outlook of KPTI Q1 Earnings - MarketBeat
Karyopharm Therapeutics raises ~$30M in private placement, adds ~$19.8M via ATM - TradingView
Karyopharm (NASDAQ: KPTI) completes $30M private placement and ATM sale - Stock Titan
Karyopharm: Putting The Phase 3 Trial In Context (NASDAQ:KPTI) - Seeking Alpha
Karyopharm Therapeutics jumps 18%, raises $30M privately - MSN
KPTI Stock Down on Mixed Phase III Myelofibrosis Combo Study Data - Yahoo Finance
KPTI: Baird Lowers Price Target, Maintains Outperform Rating | K - GuruFocus
Karyopharm Therapeutics (NASDAQ:KPTI) Price Target Lowered to $15.00 at Robert W. Baird - MarketBeat
HC Wainwright Lowers Karyopharm Therapeutics (NASDAQ:KPTI) Price Target to $8.00 - MarketBeat
H.C. Wainwright cuts Karyopharm stock price target on trial results By Investing.com - Investing.com Canada
HC Wainwright & Co. Lowers Price Target on Karyopharm Therapeuti - GuruFocus
Karyopharm raises $30M in private placement with RA Capital By Investing.com - Investing.com Australia
Karyopharm Therapeutics Falls As Pivotal Trial Hits Spleen Goal But Misses Symptom Mark - Sahm
Karyopharm Therapeutics Inc. (KPTI) Discusses Top Line Results From Phase III SENTRY Trial in MyelofibrosisSlideshow (NASDAQ:KPTI) 2026-03-25 - Seeking Alpha
Karyopharm myeloma drug yields mixed data in myelofibrosis trial - BioPharma Dive
Karyopharm’s myelofibrosis trial meets one of two primary goals By Investing.com - Investing.com India
KPTI Shares Fall Following Varied Results from Phase III Myelofibrosis Combination Study - Bitget
Karyopharm Therapeutics falls as pivotal trial hits spleen goal but misses symptom mark - msn.com
Leerink cuts Karyopharm stock price target on mixed trial data By Investing.com - ca.investing.com
Why Is Karyopharm Therapeutics Stock Trading Lower Today?Karyopharm Therapeutics (NASDAQ:KPTI) - Benzinga
Karyopharm’s Phase 3 SENTRY Trial Shows Significant Spleen Reduction and Promising Overall Survival in Myelofibrosis with Selinexor Plus Ruxolitinib 1 - Minichart
Karyopharm phase III Sentry entry bucks rux in MF; to FDA next - bioworld.com
Karyopharm, looking to jump-start Xpovio, reports mixed results in myelofibrosis - Fierce Pharma
Karyopharm research and financing developments - The Pharma Letter
Karyopharm shares rise 10% after mixed Phase 3 SENTRY trial results - MSN
KPTI Stock Faces Uncertainty Amid Financial Challenges - StocksToTrade
Karyopharm Therapeutics SENTRY Trial Hits Spleen Endpoint, Shows Early Survival Signal in Myelofibrosis - MarketBeat
RBC Capital maintains Outperform on Karyopharm stock after trial data By Investing.com - Investing.com Australia
RBC Capital maintains Outperform on Karyopharm stock after trial data - Investing.com
Karyopharm Therapeutics (KPTI) Stock Plunges 12.71% on $30M Financing Announcement - Blockonomi
Karyopharm (KPTI) Announces Positive Phase 3 Trial Results for S - GuruFocus
Karyopharm Therapeutics Inc. (KPTI) Stock: Drops 12.71% After $30M Private Placement Deal - CoinCentral
Karyopharm Shares Jump 10% Following Mixed Phase 3 Trial Outcomes on Myelofibrosis Treatment - stockinvest.us
Why Did KPTI Stock Tank 13% In Pre-Market Today? - Stocktwits
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):